Spero Therapeutics Inc

2HA

Company Profile

  • Business description

    Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

  • Contact

    675 Massachusetts Avenue
    14th Floor
    CambridgeMA02139
    USA

    T: +1 857 242-1600

    E: [email protected]

    https://www.sperotherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    32

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,510.7043.700.52%
CAC 407,873.8323.730.30%
DAX 4023,638.5672.020.31%
Dow JONES (US)42,140.43269.67-0.64%
FTSE 1008,602.922.06-0.02%
HKSE23,108.27441.19-1.87%
NASDAQ19,010.09301.741.61%
Nikkei 22538,183.26539.001.43%
NZX 50 Index12,781.185.56-0.04%
S&P 5005,886.5542.360.72%
S&P/ASX 2008,269.0035.500.43%
SSE Composite Index3,374.875.630.17%

Market Movers